Deep brain stimulation targeting the fornix for mild Alzheimer dementia: design of the ADvance randomized controlled trial

Recommended Citation Holroyd, Kathryn B.; Fosdick, Lisa; Smith, Gwenn S.; Leoutsakos, Jeannie Marie; Munro, Cynthia A.; Oh, Esther S.; Drake, Kristen E.; Rosenberg, Paul B.; Anderson, William S.; Salloway, Stephen; Pendergrass, J. Cara; Burke, Anna D.; Wolk, David A.; Tang-Wai, David F.; Ponce, Francisco A.; Asaad, Wael F.; Sabbagh, Marwan N.; Okun, Michael S.; Baltuch, Gordon; and al., et, "Deep Brain Stimulation Targeting the Fornix for Mild Alzheimer Dementia: Design of the ADvance Randomized Controlled Trial" (2015). Neurology Articles. 30. https://scholar.barrowneuro.org/neurology/30

[1]  D. Delis,et al.  California Verbal Learning Test--Second Edition , 2016 .

[2]  K. Zilles,et al.  Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer’s dementia , 2014, Molecular Psychiatry.

[3]  Ron Dumont,et al.  California Verbal Learning Test, Second Edition , 2014 .

[4]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[5]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[6]  V. Visser-Vandewalle,et al.  Deep Brain Stimulation as a Tool for Improving Cognitive Functioning in Alzheimer’s Dementia: A Systematic Review , 2013, Front. Psychiatry.

[7]  Evan Fletcher,et al.  Loss of fornix white matter volume as a predictor of cognitive impairment in cognitively normal elderly individuals. , 2013, JAMA neurology.

[8]  E. Siemers,et al.  A phase 3 trial of semagacestat for treatment of Alzheimer's disease. , 2013, The New England journal of medicine.

[9]  H. Steinbusch,et al.  Deep brain stimulation of the forniceal area enhances memory functions in experimental dementia: The role of stimulation parameters , 2013, Brain Stimulation.

[10]  Susumu Mori,et al.  The Fornix Sign: A Potential Sign for Alzheimer's Disease Based on Diffusion Tensor Imaging , 2012, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[11]  Andreea Oliviana Diaconescu,et al.  Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease. , 2012, Archives of neurology.

[12]  Katherine E. Prater,et al.  Functional connectivity tracks clinical deterioration in Alzheimer's disease , 2012, Neurobiology of Aging.

[13]  R. Ihl,et al.  Detecting treatment effects with combinations of the ADAS‐cog items in patients with mild and moderate Alzheimer's disease , 2012, International journal of geriatric psychiatry.

[14]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[15]  Barbara Stanley,et al.  The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. , 2011, The American journal of psychiatry.

[16]  B. Vellas,et al.  Long-term progression of Alzheimer’s disease in patients under antidementia drugs , 2011, Alzheimer's & Dementia.

[17]  G. Winocur,et al.  Memory rescue and enhanced neurogenesis following electrical stimulation of the anterior thalamus in rats treated with corticosterone , 2011, Experimental Neurology.

[18]  M. Sugishita,et al.  [Clinical Dementia Rating (CDR)]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[19]  R. Wennberg,et al.  A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease , 2010, Annals of neurology.

[20]  Frank Tennigkeit,et al.  Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? , 2010, Alzheimer's Research & Therapy.

[21]  Brad J Kolls,et al.  A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE , 2010, Neurology.

[22]  Owen Carmichael,et al.  Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative , 2010, Alzheimer's & Dementia.

[23]  W. Jagust,et al.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.

[24]  R. Green,et al.  Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. , 2009, JAMA.

[25]  Heidi Johansen-Berg,et al.  Fornix Microstructure Correlates with Recollection But Not Familiarity Memory , 2009, The Journal of Neuroscience.

[26]  Osamu Abe,et al.  Tract-specific analysis of white matter pathways in healthy subjects: a pilot study using diffusion tensor MRI , 2009, Neuroradiology.

[27]  Lisa Geraci,et al.  How Well Do the ADAS-cog and its Subscales Measure Cognitive Dysfunction in Alzheimer’s Disease? , 2009, Dementia and Geriatric Cognitive Disorders.

[28]  Kwun Chuen Gary Chan,et al.  Regionally-specific diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease , 2009, NeuroImage.

[29]  N. Herrmann,et al.  Review: Therapy for Alzheimer's disease: how effective are current treatments? , 2009, Therapeutic advances in neurological disorders.

[30]  Keith A. Johnson,et al.  Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease , 2009, The Journal of Neuroscience.

[31]  A. Lozano,et al.  Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression , 2008, Biological Psychiatry.

[32]  Sid E O'Bryant,et al.  Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. , 2008, Archives of neurology.

[33]  M. Sano,et al.  Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.

[34]  K. Blennow,et al.  Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease , 2008, Annals of neurology.

[35]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[36]  A. Lozano,et al.  The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation. , 2008, Journal of neurosurgery.

[37]  R. Wennberg,et al.  Memory enhancement induced by hypothalamic/fornix deep brain stimulation , 2008, Annals of neurology.

[38]  Justin L. Vincent,et al.  Disruption of Large-Scale Brain Systems in Advanced Aging , 2007, Neuron.

[39]  P. Aisen,et al.  A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease , 2006, Neurology.

[40]  A. Wall,et al.  Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer’s disease , 2006, Journal of Neural Transmission.

[41]  A. Convit,et al.  Reduced hippocampal metabolism in MCI and AD , 2005, Neurology.

[42]  A. Lozano,et al.  Deep Brain Stimulation for Treatment-Resistant Depression , 2005, Neuron.

[43]  Satoshi Minoshima,et al.  Detection of Early Alzheimer's Disease , 2004 .

[44]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[45]  Steven Potkin,et al.  Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. , 2003, Archives of neurology.

[46]  T. Finucane.  Cholinesterase inhibitors for Alzheimer's disease , 2002, The Lancet.

[47]  Laura E. Gibbons,et al.  Assessing Quality of Life in Older Adults With Cognitive Impairment , 2002, Psychosomatic medicine.

[48]  G. Alexander,et al.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.

[49]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[50]  P. Krack,et al.  Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. , 2001, The New England journal of medicine.

[51]  C. Lyketsos,et al.  The General Medical Health Rating: A Bedside Global Rating of Medical Comorbidity in Patients with Dementia , 1999, Journal of the American Geriatrics Society.

[52]  J. Dostrovsky,et al.  Phantom sensations generated by thalamic microstimulation , 1998, Nature.

[53]  J. Morris,et al.  Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.

[54]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[55]  J. Price,et al.  Cerebral amyloid deposition and diffuse plaques in ``normal'' aging , 1996, Neurology.

[56]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[57]  K. Davis.  Cholinesterase Inhibitors in Alzheimer's Disease , 1994, Neuropsychopharmacology.

[58]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[59]  J. Miller,et al.  Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. , 1993, Archives of neurology.

[60]  M J de Leon,et al.  Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. , 1992, Archives of neurology.

[61]  D. Gaffan,et al.  Amnesia following damage to the left fornix and to other sites. A comparative study. , 1991, Brain : a journal of neurology.

[62]  G. Alexopoulos,et al.  Cornell scale for depression in dementia , 1988, Biological Psychiatry.

[63]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[64]  R. Katzman.,et al.  Pathological verification of ischemic score in differentiation of dementias , 1980, Annals of neurology.

[65]  R. C. Young,et al.  A Rating Scale for Mania: Reliability, Validity and Sensitivity , 1978, British Journal of Psychiatry.

[66]  F. Vogel,et al.  The limbic system in Alzheimer's disease. A neuropathologic investigation. , 1976, The American journal of pathology.

[67]  Arthur L. Benton,et al.  Word fluency and brain damage , 1967 .

[68]  R. Reitan.  Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .

[69]  P. Robert,et al.  Symptomatic treatment of memory decline in Alzheimer's disease by deep brain stimulation: a feasibility study. , 2013, Journal of Alzheimer's disease : JAD.

[70]  P. A. House,et al.  Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial , 2009 .